US Edition
Published • loading... • Updated
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Eupraxia Pharmaceuticals raised $63 million through a public offering to fund development of its Diffusphere drug delivery technology targeting unmet medical needs.
- On March 11, 2026, Petco Health and Wellness reported profitability ahead of its outlook and said it lowered its leverage ratio from 4.2X to 3X by the end of 2025.
- Management's operational reset, led by senior hires and model changes, enabled Petco to rebuild its economic model and exceed profitability goals, said Joel Anderson.
- Balance-Sheet items include net sales of $6.0 billion, adjusted EBITDA of $408.2 million, cash of $256.7 million, and net debt of $347.9 million for 2025.
- Guidance assumes Petco Health and Wellness Company, Inc. will have net sales flat to up 1.5% and adjusted EBITDA of $415 million to $430 million in fiscal 2026, with Q1 2026 adjusted EBITDA of $92 million to $94 million.
- Petco cautioned that forward-looking statements in SEC filings and earnings release are based on current expectations and subject to risks, with no duty to update except as required by law.
Insights by Ground AI
61 Articles
61 Articles
The Billings Gazette+11 Reposted by 11 other sources
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025.
·Billings, United States
Read Full Article
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central…
Coverage Details
Total News Sources61
Leaning Left12Leaning Right3Center19Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 35%
C 56%
Factuality
To view factuality data please Upgrade to Premium
